Pharmaceuticals India News
  • Home
  • Brands
    • Alkem
    • Apollo Hospital
    • Aurobindo Pharma
    • Biocon
    • Cipla
    • Divi’s Laboratories
    • Dr Reddy’s
    • Fortis
    • Glenmark
    • Lupin
    • Mankind Pharma
    • Natco
    • Pfizer
    • Piramal Pharma
    • Sun Pharma
    • Torrent Pharma
    • Zydus
Select Page

A Comparative Analysis of Road Infrastructure: Bengaluru versus Ecuador

by Team Small News | Mar 27, 2025 | Biocon, Pharma

Kiran Mazumdar Shaw, the founder of Biocon, recently expressed her disappointment with Bengaluru’s civic infrastructure on social media. She shared a picture of clean streets in San Cristobal Island, Ecuador, and compared it unfavorably to Bengaluru, stating,...

Biocon’s novel pharmaceutical blend, including norepinephrine and innovative therapies, achieves coveted USFDA clearance.

by Team Small News | Mar 24, 2025 | Biocon, Pharma

Biocon’s arm, Biocon Pharma, has received approval for its Norepinephrine Bitartrate Injection in the US, expanding its portfolio of complex injectables. The injection will be used to treat adults with acute hypotension and sodium nitroprusside/control of blood...

Eli Lilly expands its global footprint by introducing Mounjaro, a groundbreaking weight management medication, to the Indian market.

by Team Small News | Mar 22, 2025 | Biocon, Cipla, Lupin, Mankind, Natco, Pharma

Eli Lilly & Co. has launched its anti-obesity drug Mounjaro in India, making it the country’s first treatment of its kind. The drug, which is used to treat obesity and type-2 diabetes, works by activating hormones that help reduce the amount of sugar in the...

Biotechnology company Biocon is facing a patent infringement lawsuit from Impax over its generic version of Rytary, a US-approved medication.

by Team Small News | Mar 21, 2025 | Biocon, Pharma

Biocon, an Indian generic drug manufacturer, has been hit with a patent infringement complaint in the US District of New Jersey by Impax Laboratories. The complaint is related to Biocon’s Abbreviated New Drug Application (ANDA) to sell a generic version of the...

Johor is set to become Asia’s largest insulin hub, thanks to a RM1.1 billion investment boost from Biocon, as reported in the New Straits Times.

by Team Small News | Mar 18, 2025 | Biocon, Pharma

Johor has emerged as a prime location to become Asia’s largest insulin hub, with Indian biotech major Biocon’s RM1.1 billion (approximately US$274 million) investment to establish a manufacturing facility in the state. Biocon, one of India’s largest...
Next Entries »

_________

Pharna Brands

  • Alkem
  • Apollo Hospital
  • Aurobindo Pharma
  • Biocon
  • Cipla
  • Divi’s Laboratories
  • Dr Reddy’s
  • Fortis
  • Glenmark
  • Lupin
  • Mankind Pharma
  • Natco
  • Pfizer
  • Piramal Pharma
  • Sun Pharma
  • Torrent Pharma
  • Zydus
  • Alkem
  • Apollo Hospital
  • Aurobindo Pharma
  • Biocon
  • Cipla
  • Torrent Pharma
  • Divi’s Laboratories
  • Dr Reddy’s
  • Fortis
  • Glenmark
  • Lupin
  • Zydus
  • Mankind Pharma
  • Natco
  • Pfizer
  • Piramal Pharma
  • Sun Pharma

    Designed by Elegant Themes | Powered by WordPress